1.   

On 13 April 2021, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).

This notification concerns the following undertakings:

—	CSS Holding AG (‘CSS’, Switzerland),

—	Visana Beteiligungen AG (‘Visana’, Switzerland),

—	Zur Rose Group AG (‘Zur Rose’, Switzerland),

—	medi24 AG (‘medi24’, Switzerland), controlled by Allianz SE, and

—	WELL Gesundheit AG (‘WELL’, Switzerland).

CSS, Visana, Zur Rose and medi24 acquire within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation joint control of WELL.

The concentration is accomplished by way of purchase of shares in a newly created company constituting a joint venture.

2.   

The business activities of the undertakings concerned are:

—	CSS and its subsidiaries offer healthcare insurance, accident insurance and supplementary and property insurance in Switzerland,

—	Visana and its subsidiaries offer compulsory healthcare insurance, supplementary and property insurance and accident insurance in Switzerland,

—	Zur Rose is an online pharmacy and a marketplace for health and personal care products commonly sold in pharmacies,

—	medi24 is a telemedical competence centre with the status of a Swiss medical practice,

—	WELL will be active in the development and operation of a digital health platform for the Swiss market.

3.   

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2), it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4.   

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.10197 — CSS/Visana/Zur Rose/medi24/WELL JV

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË